Ciboy personal page - To The Moon

Ciboy

No personal profile

10Follow

1Followers

0Topic

0Badge

2024-07-26

Great article, would you like to share it?

@hongg:$Tesla Motors(TSLA)$ a downgrade today. Will it go below 200 by EOW?

2024-07-26

Great article, would you like to share it?

@SPACE ROCKET:$CLSK 20240802 18.5 CALL$ Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!

2024-07-26

Great article, would you like to share it?

@SPACE ROCKET:$CleanSpark, Inc.(CLSK)$ $Marathon Digital Holdings Inc(MARA)$ My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤 OMG 🤦‍♀️🤦‍♀️ @Barcode @nomadic_m @icycrystal

2021-09-11

Good buy?

Why Novavax Stock Slipped Thursday

2021-08-23

Thumbs up. Like please

Pfizer and BioNTech SE shares surged in premarket trading

2021-08-21

Good article

Sorry, the original content has been removed

2021-08-20

The 3 Rs.

2021-06-08

Like and comment

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582794558746184","uuid":"3582794558746184","gmtCreate":1619707409658,"gmtModify":1619707409658,"name":"Ciboy","pinyin":"ciboy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":10,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":331534682796192,"gmtCreate":1721948669292,"gmtModify":1721948671255,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534682796192","repostId":"331365772005472","repostType":1,"repost":{"id":331365772005472,"gmtCreate":1721907793482,"gmtModify":1721907797135,"author":{"id":"3578638769183965","authorId":"3578638769183965","name":"hongg","avatar":"https://static.tigerbbs.com/5a7a0b4bab6ad61e3bd4f1a19c4d1a03","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578638769183965","idStr":"3578638769183965"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; a downgrade today. Will it go below 200 by EOW?","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; a downgrade today. Will it go below 200 by EOW?","text":"$Tesla Motors(TSLA)$ a downgrade today. Will it go below 200 by EOW?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331365772005472","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":331534138331240,"gmtCreate":1721948660854,"gmtModify":1721948662841,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534138331240","repostId":"331398691086488","repostType":1,"repost":{"id":331398691086488,"gmtCreate":1721915434953,"gmtModify":1746656938862,"author":{"id":"4093561479903300","authorId":"4093561479903300","name":"SPACE ROCKET","avatar":"https://community-static.tradeup.com/news/5f9c495dd9f776573648d60f1476fdab","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4093561479903300","idStr":"4093561479903300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/CLSK 20240802 18.5 CALL\">$CLSK 20240802 18.5 CALL$&nbsp;</a>Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","listText":"<a href=\"https://ttm.financial/OPT/CLSK 20240802 18.5 CALL\">$CLSK 20240802 18.5 CALL$&nbsp;</a>Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","text":"$CLSK 20240802 18.5 CALL$ Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331398691086488","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1919,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":331534055887072,"gmtCreate":1721948644797,"gmtModify":1721948648579,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534055887072","repostId":"331416561946720","repostType":1,"repost":{"id":331416561946720,"gmtCreate":1721920193370,"gmtModify":1721982707817,"author":{"id":"4093561479903300","authorId":"4093561479903300","name":"SPACE ROCKET","avatar":"https://community-static.tradeup.com/news/5f9c495dd9f776573648d60f1476fdab","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4093561479903300","idStr":"4093561479903300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$ </a>&nbsp;<a href=\"https://ttm.financial/S/MARA\">$Marathon Digital Holdings Inc(MARA)$ </a>&nbsp; My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤&nbsp;&nbsp;OMG&nbsp;🤦‍♀️🤦‍♀️ <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4142551860919612\">@nomadic_m </a>&nbsp;<a href=\"https://ttm.financial/U/4132300740238052\">@icycrystal </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$ </a>&nbsp;<a href=\"https://ttm.financial/S/MARA\">$Marathon Digital Holdings Inc(MARA)$ </a>&nbsp; My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤&nbsp;&nbsp;OMG&nbsp;🤦‍♀️🤦‍♀️ <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4142551860919612\">@nomadic_m </a>&nbsp;<a href=\"https://ttm.financial/U/4132300740238052\">@icycrystal </a>&nbsp;","text":"$CleanSpark, Inc.(CLSK)$ $Marathon Digital Holdings Inc(MARA)$ My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤 OMG 🤦‍♀️🤦‍♀️ @Barcode @nomadic_m @icycrystal","images":[{"img":"https://community-static.tradeup.com/news/ed038a839300957d62869fb64c76e84a","width":"1440","height":"695"},{"img":"https://community-static.tradeup.com/news/af1f7492b9028567ec847cb80a851740","width":"1024","height":"1024"},{"img":"https://community-static.tradeup.com/news/feb091e9c1eb247badb3611373625d3f","width":"1024","height":"1024"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331416561946720","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881119079,"gmtCreate":1631316218291,"gmtModify":1676530525302,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Good buy?","listText":"Good buy?","text":"Good buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881119079","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://ttm.financial/m/news/1158877090?lang=en_US&edition=fundamental","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p>\n<blockquote>\n <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>\n <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>\n <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p>\n<p><b>So what</b></p>\n<p>SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p>\n<p>The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p>\n<p>This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p>\n<p><b>Now what</b></p>\n<p>Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p>\n<p>Novavax fell over 2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835841840,"gmtCreate":1629706755480,"gmtModify":1676530105833,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Thumbs up. Like please","listText":"Thumbs up. Like please","text":"Thumbs up. Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835841840","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://ttm.financial/m/news/1104804215?lang=en_US&edition=fundamental","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-23 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836511851,"gmtCreate":1629506796773,"gmtModify":1676530060186,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Good article","listText":"Good article","text":"Good article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836511851","repostId":"2160176501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838259531,"gmtCreate":1629415328623,"gmtModify":1676530031024,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"The 3 Rs.","listText":"The 3 Rs.","text":"The 3 Rs.","images":[{"img":"https://static.tigerbbs.com/2b73a296bec84f92723b409fc422943f","width":"1440","height":"1835"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838259531","isVote":1,"tweetType":1,"viewCount":1883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114747983,"gmtCreate":1623108223142,"gmtModify":1704196056249,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114747983","repostId":"2141342255","repostType":4,"isVote":1,"tweetType":1,"viewCount":2484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":114747983,"gmtCreate":1623108223142,"gmtModify":1704196056249,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114747983","repostId":"2141342255","repostType":4,"isVote":1,"tweetType":1,"viewCount":2484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835841840,"gmtCreate":1629706755480,"gmtModify":1676530105833,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Thumbs up. Like please","listText":"Thumbs up. Like please","text":"Thumbs up. Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835841840","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://ttm.financial/m/news/1104804215?lang=en_US&edition=fundamental","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-23 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881119079,"gmtCreate":1631316218291,"gmtModify":1676530525302,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Good buy?","listText":"Good buy?","text":"Good buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881119079","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://ttm.financial/m/news/1158877090?lang=en_US&edition=fundamental","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p>\n<blockquote>\n <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>\n <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>\n <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p>\n<p><b>So what</b></p>\n<p>SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p>\n<p>The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p>\n<p>This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p>\n<p><b>Now what</b></p>\n<p>Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p>\n<p>Novavax fell over 2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836511851,"gmtCreate":1629506796773,"gmtModify":1676530060186,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Good article","listText":"Good article","text":"Good article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836511851","repostId":"2160176501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":331534682796192,"gmtCreate":1721948669292,"gmtModify":1721948671255,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534682796192","repostId":"331365772005472","repostType":1,"repost":{"id":331365772005472,"gmtCreate":1721907793482,"gmtModify":1721907797135,"author":{"id":"3578638769183965","authorId":"3578638769183965","name":"hongg","avatar":"https://static.tigerbbs.com/5a7a0b4bab6ad61e3bd4f1a19c4d1a03","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578638769183965","authorIdStr":"3578638769183965"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; a downgrade today. Will it go below 200 by EOW?","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v>&nbsp; a downgrade today. Will it go below 200 by EOW?","text":"$Tesla Motors(TSLA)$ a downgrade today. Will it go below 200 by EOW?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331365772005472","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":331534138331240,"gmtCreate":1721948660854,"gmtModify":1721948662841,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534138331240","repostId":"331398691086488","repostType":1,"repost":{"id":331398691086488,"gmtCreate":1721915434953,"gmtModify":1746656938862,"author":{"id":"4093561479903300","authorId":"4093561479903300","name":"SPACE ROCKET","avatar":"https://community-static.tradeup.com/news/5f9c495dd9f776573648d60f1476fdab","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4093561479903300","authorIdStr":"4093561479903300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/CLSK 20240802 18.5 CALL\">$CLSK 20240802 18.5 CALL$&nbsp;</a>Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","listText":"<a href=\"https://ttm.financial/OPT/CLSK 20240802 18.5 CALL\">$CLSK 20240802 18.5 CALL$&nbsp;</a>Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","text":"$CLSK 20240802 18.5 CALL$ Let's see how this goes. Wanted to sell 30 lots but Tiger has been crashing on me recently and not responding accurately to what I type. Kept registering 33 when I keyed in 30. So selling 33 it is!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331398691086488","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1919,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":331534055887072,"gmtCreate":1721948644797,"gmtModify":1721948648579,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331534055887072","repostId":"331416561946720","repostType":1,"repost":{"id":331416561946720,"gmtCreate":1721920193370,"gmtModify":1721982707817,"author":{"id":"4093561479903300","authorId":"4093561479903300","name":"SPACE ROCKET","avatar":"https://community-static.tradeup.com/news/5f9c495dd9f776573648d60f1476fdab","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4093561479903300","authorIdStr":"4093561479903300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$ </a>&nbsp;<a href=\"https://ttm.financial/S/MARA\">$Marathon Digital Holdings Inc(MARA)$ </a>&nbsp; My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤&nbsp;&nbsp;OMG&nbsp;🤦‍♀️🤦‍♀️ <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4142551860919612\">@nomadic_m </a>&nbsp;<a href=\"https://ttm.financial/U/4132300740238052\">@icycrystal </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$ </a>&nbsp;<a href=\"https://ttm.financial/S/MARA\">$Marathon Digital Holdings Inc(MARA)$ </a>&nbsp; My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤&nbsp;&nbsp;OMG&nbsp;🤦‍♀️🤦‍♀️ <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4142551860919612\">@nomadic_m </a>&nbsp;<a href=\"https://ttm.financial/U/4132300740238052\">@icycrystal </a>&nbsp;","text":"$CleanSpark, Inc.(CLSK)$ $Marathon Digital Holdings Inc(MARA)$ My trades are not behaving because of this 😵‍💫😵‍💫🤯🤯 I ended up selling funny number of lots because of wonky Tiger that keeps crashing. Samsung keeps asking me to put Tiger Brokers to deep sleep! 😴 💤 OMG 🤦‍♀️🤦‍♀️ @Barcode @nomadic_m @icycrystal","images":[{"img":"https://community-static.tradeup.com/news/ed038a839300957d62869fb64c76e84a","width":"1440","height":"695"},{"img":"https://community-static.tradeup.com/news/af1f7492b9028567ec847cb80a851740","width":"1024","height":"1024"},{"img":"https://community-static.tradeup.com/news/feb091e9c1eb247badb3611373625d3f","width":"1024","height":"1024"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/331416561946720","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838259531,"gmtCreate":1629415328623,"gmtModify":1676530031024,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582794558746184","authorIdStr":"3582794558746184"},"themes":[],"htmlText":"The 3 Rs.","listText":"The 3 Rs.","text":"The 3 Rs.","images":[{"img":"https://static.tigerbbs.com/2b73a296bec84f92723b409fc422943f","width":"1440","height":"1835"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838259531","isVote":1,"tweetType":1,"viewCount":1883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}